Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07185100

Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions. The WE-CARE-HF-CMR study, conducted in large cities/metropol areas in Germany ( > 1.000.000 inhabitants), aims to close this gap by evaluating the feasibility of a mobile, telemedicinemonitored HF-screening approach combining cardiac magnetic resonance imaging (CMR), quality of life assessment and laboratory tests as key elements in asymptomatic patients at risk. WE-CARE-HF-CMR will provide a proposal for a comprehensive, contemporary screening approach for patients at risk to develop HF tailored to the needs of the target population. This will provide important new information on the prevalence of asymptomatic HF in at-risk patients in urban versus rural areas.

The results of the study will be compared with the results from the "HERZCheck'' trial, which provides data from approximately 4,500 participants in rural areas in Germany and has already been completed (NCT05122793).

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year–69 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The WE-CARE-HF-CMR-study is a cross-sectional, nationwide prospective, community-based observational study to improve the diagnosis of heart failure in urban populations with characteristic risk factors for the occurrence of heart failure using telemedically-supervised mobile diagnostic units. The central diagnostic methods employed in the assessed screening routine comprise a questionnaire-based medical history, laboratory testing and a standardized, non-invasive imaging examination.

Within the framework of the study, 600 subjects aged 40 to 69 years and of male, female or diverse gender, who have characteristic risk factors for the occurrence of asymptomatic heart failure will be examined.

The central diagnostic imaging method of the study is a standardized, needle- as well as stress- and contrast-agent-free CMR exam. The examinations are carried out in mobile MRI diagnostic units at various clinic locations in 5 major cities (> 1.000.000 residents) in Germany. The various clinics were recommended as locations because they offer good infrastructural conditions for setting up the mobile MRI diagnostic units, which are 27 t truck units, and because emergency medical care for the study participants can also be guaranteed. The medical staff of the clinics is not involved in the study. The potential study participants will be informed by the investigators of the DHZC in a video call either in a room rented specifically for this purpose or in an accompanying vehicle of the mobile MRI diagnostic unit. The consent of the study participants is also obtained via telemedicine and in accordance with current legal requirements in Germany. The planned examinations in the mobile diagnostic unit will be carried out exclusively by the staff of the company operating the MRI units on behalf of and under the telemedical supervision of the investigators and the study management of the DHZC, acting as the central unit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Asymptomatic subjects with:

  • chronic diabetes mellitus (known/diagnosed and/or antidiabetic medication and/or elevated HbA1C) and/or
  • renal impairment (known/diagnosed CKD and/or in laboratory CKD III° or higher) and/or
  • Hypertension (known/diagnosed and/or antihypertensive medication/treatment) and/or
  • Hypercholesterolaemia (known/diagnosed and/or antilipid medication/treatment) and/or
  • Obesity (known/diagnosed and/or BMI > 30 (kg/m²)) and/or
  • Smoker (known/diagnosed and/or current/previous and/or medication/treatment)
  • Age 40-69 years
  • female or male or diverse sex
  • Ability to provide informed consent
  • Provision of Informed Consent

Exclusion criteria

  • Inability to provide written informed consent
  • Diagnosed heart failure or previously detected reduced ejection fraction
  • General MRI exclusion criteria (pacemaker, defibrillator, intracranial aneurysm clips, metallic foreign bodies in the eyes)
  • Any MRI exclusion criteria not listed here, as determined by the MRI laboratory performing the procedure
  • Haemodynamically unstable participants (heart rate < 45/min, systolic blood pressure < 90 mmHg)
  • Claustrophobia
  • Sensorineural hearing loss of 30 dB or more and tinnitus
  • Acute mental disorders requiring therapy
  • In the presence of pregnancy

Treatment and study plan

Primary outcomes

  1. Prevalence of asymptomatic pre-heart failure (stage B) in an urban population

    Time frame: at baseline

    Asymptomatic pre-heart failure (stage B) is defined as CMR-derived global longitudinal strain (GLS) ≥ -15%

Secondary outcomes

  1. Prevalence of chronic kidney disease (CKD)

    Time frame: at baseline

    CKD is defined as eGFR < 60%

  2. Adherence to therapy

    Time frame: 1, 5 years and 10 years later

    Assessed using the MARS-10 questionnaire

Study contacts

Contact information is provided by the study sponsor or research team.

Dr. Gisela Thiede

CONTACT

[email protected]

+4915209192843

Prof. Dr. Sebastian Kelle

CONTACT

[email protected]

+493045931182

Sponsors and collaborators

Lead sponsor

German Heart Institute

Other

Collaborators

  • AstraZeneca
  • Deutsche Herzstiftung
  • Deutsches Herzzentrum der Charité, Berlin
  • German Heart Center Foundation
  • Nationale Herzallianz (NHA)
  • Philips Healthcare

Registry information

Official study title

A Prospective, Cross-sectional, Nationwide Community-based Observational Study to Determine the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

Acronym: WE-CARE-HF-CMR

Important dates

Study start
2025
Primary completion
2026
Study completion
2036
First posted
Sep 22, 2025
Registry last updated
Apr 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.